CSIMarket


Prevail Therapeutics Inc   (PRVL)
Other Ticker:  
 


 

Prevail Therapeutics Inc

PRVL's Financial Statements and Analysis



Prevail Therapeutics Inc narrowed third quarter of 2020 net loss per share of $-0.55 compare to net loss per share of $-0.62 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.66 realized in previous quarter.


third quarter of 2020
Earnings Per Share Revenues
$ -0.55 $  0 Mill
$+0.07     Unch.    



Prevail Therapeutics Inc 's Revenue fell by 0 % in third quarter of 2020 (Sep 30 2020) year on year, to $0 million and declined by sequentially.


Prevail Therapeutics Inc is

More on PRVL's Income Statement



Prevail Therapeutics Inc 's in thethird quarter of 2020 recorded net loss of $-18.587 million, an improvement compare to net loss of $-20.299 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-22.100 million realized in previous quarter.

More on PRVL's Growth

Prevail Therapeutics Inc Inventories
In Sep 30 2020 company's net cash and cash equivalents decreased by $-29 million, capital expenditures grew by -0.512-66.80%, to $0 millions compare to same quarter a year ago

More on PRVL's Cash flow Statement


Prevail Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Prevail Therapeutics Inc payed $ -2.02 cash per share, on a free-cash flow basis .

Book value fell by -12.94 % sequentially to $3.35 per share, -115.79% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.35 per share from $ 3.84.

Company issued 0.17 million shares or 0.51 % in Sep 30 2020.


More on PRVL's Dividends

 Market Capitalization (Millions) 774
 Shares Outstanding (Millions) 34
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) -101
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Prevail Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Prevail Therapeutics Inc had negative $ -2.02 cash flow per share, on a free-cash flow basis .

Book value fell by -12.94 % sequentially to $3.35 per share, -115.79% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.35 per share from $ 3.84.

Company issued 0.17 million shares or 0.51 % in Sep 30 2020.


More on PRVL's Balance Sheets

 Market Capitalization (Millions) 774
 Shares Outstanding (Millions) 34
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) -101
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   



Date modified: -0001-11-30T00:00:00+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com